Marsh McLennan Analysts Recommendations and Consensus

MMC -- USA Stock  

USD 84.06  1.68  0.02%

The current analyst and expert consensus on Marsh McLennan is Buy with 4 hold recommendations. The current projected target price consensus is 73.25 with 8 analysts opinions. One of the most common ways Marsh McLennan Compa analysists use to provide buy or sell recommendation to public are conference calls analysis and financial statements evaluations. Some experts can also talk to Marsh McLennan vendors, executives, and/or customers. Marsh McLennan recommendation module provides expert sentiment on the projected Marsh McLennan Compa target price to derive its highest and lowest estimates based on target price standard deviation of 4.496. Please see also Macroaxis Advice on Marsh McLennan to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the prospective of investor risk tolerance and investment horizon.

Marsh McLennan Target Price Consensus

Number of Opinions14
Lowered Outlook0
Raized Outlook0
Buy
Macroaxis Recommendation   Exposure   Valuation

Marsh McLennan Target Price Projection

Current Price

Marsh McLennan Market Quote

Low Price82.43Odds
High Price84.18Odds

84.06

Target Price

Analyst Consensus On Target Price

Low Estimate65.0Odds
High Estimate78.0Odds
Number of Analysts8
Standard Deviation4.496

73.25

Marsh McLennan Analysit Ratings

Average Consensus

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  

Current Thematic Trending

Real Goods Solar
Purchased few shares
Traded 3 days ago for 0.52
Pharmaceutical Products
Purchased over 90 shares
Traded 3 days ago for 0.13
Synergy Pharmaceuticals
Purchased few shares
Traded 3 days ago for 0.24
Vital Therapies
Purchased over 500 shares
Traded 3 days ago for 0.26
Pharmaceutical Products
Purchased over 100 shares
Traded 3 days ago for 0.13
Top Penny
Purchased over 100 shares
Traded few days ago for 0.8
Please see also Macroaxis Advice on Marsh McLennan to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the prospective of investor risk tolerance and investment horizon. Please also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Search macroaxis.com